DexCom promotes Sayer to CEO
This article was originally published in Clinica
Executive Summary
Glucose monitoring firm DexCom has tapped its president and COO Kevin Sayer to be president and CEO. Mr Sayer succeeds Terry Gregg, who is transitioning to the role of executive chair after three years in the top spot and seven years of service with DexCom. Mr Sayer, who became the firm’s president and COO in January 2013 after working as president for two years, has served as a board member since November 2007. Prior to this he was chief financial officer of Biosensors International, a medtech company specializing in interventional cardiology and critical care procedures. DexCom competes with Medtronic in the continuous glucose monitor (CGM) market. In October, it gained the first FDA approval for a CGM that can wirelessly transmit data to a smartphone via a cradle. And in December its technology was approved for use with Johnson & Johnson/Animas’s Vibe insulin pump.